Control

Preclinical

OOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

Control is one of 2 therapeutic programs targeting Seroma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

SeromaCompleted

SeromaPreclinical

Completed

Competition

Competitive Landscape

1 competitor in Seroma

#DrugCompanyPhaseTrials

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 2

Control

OOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Age Related Cataracts

NCT07395986

Q3 2027

Phase 2Recruiting

Bleeding

NCT06057675

Clinical

Trials by Indication[1]

Wound1 trial

Improving Palatal Donor Site Healing and Reducing Postoperative Morbidity With Concentrated Growth Factor and Collagen Fleece: Randomized Controlled Clinical Study

Completed·IInonu University·Preclinical·NCT07367165·38 enrolled

Bleeding1 trial

Subcutaneous Tranexamic Acid in Nasal Mohs Local Flap Reconstruction: Perioperative Bleeding, Edema, and Ecchymosis

Recruiting·VVanderbilt University Medical Center·Phase 2·NCT06057675·100 enrolled

Micronutrient Deficiencies1 trial

Evaluation of Balance Tablets in Reducing Vitamin and Mineral Deficiencies in Patients Using GLP-1 Receptor Agonists for Weight Loss

Completed·GGeneral Committee of Teaching Hospitals and Institutes, Egypt·Approved·NCT06981936·150 enrolled

Chikungunya Virus Infection1 trial

A Randomized, Observer-blinded, Dose Response Phase 2 Trial to Assess the Safety and Immunogenicity of Two Different Dose Levels of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Healthy Children Aged 1 to 11 Years

Completed·VValneva Austria GmbH·Phase 2·NCT06106581·304 enrolled

Age Related Cataracts1 trial

A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With Age-Related Cataract

Active, not recruiting·OOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.·Phase 2·NCT07395986·8 enrolled

2 more indications

Seroma1 trial

Effect of Irrigation of Triamcinolone Versus Hypertonic Saline in Decreasing Seroma Post Abdominoplasty

Completed·CCairo University·Preclinical·NCT07733921·90 enrolled

Osteoarthritis, Knee1 trial

Evaluating the Efficacy of Probiotic Supplements on Osteoarthritis Patients

Completed·BBeni-Suef University·Phase 3·NCT07364578·146 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Control. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Control. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: OOcusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

Control

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Wound1 trial

Bleeding1 trial

Micronutrient Deficiencies1 trial

Chikungunya Virus Infection1 trial

Age Related Cataracts1 trial

Seroma1 trial

Osteoarthritis, Knee1 trial

References

Drug Info

Quick Facts

Related News